ATTENTION SRPT Shareholders: Lost Money On Sarepta Therapeutics, Inc.? Contact Levi & Korsinsky About Investigation

(MENAFN- ACCESSWIRE) NEW YORK, NY / ACCESS Newswire / June 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sarepta Therapeutics, Inc. ("Sarepta") (NASDAQ:SRPT) concerning possible violations of federal securities laws.

On June 16, 2025, Sarepta reported a second death linked to its gene therapy Elevidys in a non-ambulatory Duchenne muscular dystrophy patient. Accordingly, management announced it suspended commercial shipments of Elevidys in the non-ambulatory setting and paused dosing in its confirmatory ENVISION trial. Analysts note the "broader concerns around safety and regulatory scrutiny could weigh on near-term performance."
Following this news, SRPT's stock price fell by $15.24 per share, or approximately 42% to close at $20.94.
To obtain additional information, go to:

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212)363-7500 .

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171

MENAFN25062025004220003708ID1109722006